Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Topical Prescription Therapy for Psoriasis: An Expert Position Paper on Limitations of Published Guidelines and Treatment Selection With Updated Recommendations.","authors":"Joshua Burshtein, Danny Zakria, Tina Bhutani, Christopher G Bunick, Melissa Costner, Douglas DiRuggiero, Adam Friedman, Alexandra K Golant, Eingun James Song, Linda Stein Gold, Melodie Young, James Q Del Rosso","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Clinical guidelines serve as summaries of available treatment options, often coupled with specific recommendations related to treatment selection, and have benefits and limitations. Guidelines often influence how individual clinicians and/or third-party payors select treatments for patients.</p><p><strong>Objective: </strong>This expert position article reviews the intent of treatment guidelines, discusses guidelines for topical psoriasis therapies, and provides recommendations for guideline updates. The recommended approaches discussed in this article by the authors align directly with therapy selection made when clinicians incorporate shared decision-making with the individual patient.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed on May 20, 2025, using a combination of keywords \"psoriasis,\" \"topical,\" \"treatments,\" \"adverse effects,\" and \"clinical guidelines\" along with Boolean term \"AND\" for English-language original research articles, systematic reviews, narrative reviews, and meta-analyses without date restrictions. The expert position presented by the authors is limited to a discussion of topical therapies for psoriasis.</p><p><strong>Results: </strong>Clinical guidelines are developed with the overall intent of enhancing healthcare quality; however, they are not designed to constrain or supplant the clinician's decisions in determining a suitable treatment for an individual patient. Limitations of published guidelines include susceptibility to becoming outdated, lack of individualized care, variability in development, and incomplete reflection of evolving practice patterns or individual patient circumstances. The results of this review of clinical guidelines reflect the authors' conclusions from analysis of the published data, including the evaluation of how they may influence treatment selection for psoriasis by clinicians. Regarding topical psoriasis treatment, initial therapy should be supported by Food and Drug Administration (FDA) approval and labeling. These include topical roflumilast, tapinarof, topical corticosteroids, and vitamin D analogs in the same category, with no utilization management criteria dictating order of use.</p><p><strong>Limitations: </strong>The results of this review are limited by the inability to include literature that was not present in the databases queried. As this review is based on previously published data, there is potential for reporting and publication bias.</p><p><strong>Conclusion: </strong>This expert position paper encourages decision-makers to work with clinicians in providing individualized, accessible care, rather than relying solely on treatment guidelines to establish utilization management protocols. It is crucial that clinical guidelines evolve in a timely manner to reflect new therapeutic developments. Following FDA-approved indications, step-through requirements for any topical psori","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Hedgehog Pathway Inhibitors in Combination Therapy for Basal Cell Carcinoma: A Review and Narrative Synthesis.","authors":"Henry Jeon, Sarah Berman, Nathalie Zeitouni","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Hedgehog pathway inhibitors (HHIs) target aberrant Hedgehog signaling as a treatment of basal cell carcinomas (BCCs) but are limited by poorly tolerated adverse events (AEs) and development of resistance. To address these challenges, combination regimens have been investigated to improve tumor clearance while mitigating toxicity.</p><p><strong>Objective: </strong>To investigate the landscape and mechanisms behind combination therapies involving HHIs for locally advanced BCC and identify patient populations most likely to benefit from each combination regimen.</p><p><strong>Methods: </strong>Comprehensive PubMed and ClinicalTrials.gov searches were conducted for BCC combination therapies involving HHIs. Literature was analyzed following PRISMA guidelines and reviewed independently by 2 reviewers, with a third resolving conflicts. Nine studies were included, involving either vismodegib or sonidegib with concomitant itraconazole, radiation therapy, photodynamic therapy (PDT), pembrolizumab, intratumoral immunotherapy, or surgical debulking. Outcomes from combination therapies were compared to respective monotherapy outcomes from the ERIVANCE and STEVIE trials for vismodegib and the BOLT trial for sonidegib.</p><p><strong>Results: </strong>Of studies reviewed, 89% demonstrated superior outcomes measured in objective response ratio (ORR) compared to monotherapy. The highest mean ORR of 100% was demonstrated in the combination therapies of sonidegib with radiation and vismodegib with PDT. The regimen with the worst efficacy was vismodegib with pembrolizumab, with an ORR of 29%, which was worse than the respective monotherapies. Additionally, 71% of combination studies revealed a smaller percentage of patients lost to AE when compared to the respective monotherapy trials. Most tolerable combinations included sonidegib with itraconazole, sonidegib with radiation, and vismodegib with intratumoral immunotherapy. Lastly, 75% of combination therapy studies reported a better tolerability profile when compared to monotherapy.</p><p><strong>Limitations: </strong>Limitations included the low number of studies in the literature on HHI combination therapies, small study population sizes, lack of heterogeneity of regimens, and study designs involving case reports and series.</p><p><strong>Conclusion: </strong>Combination strategies for HHI therapy represent a promising avenue to optimize efficacy, improve tolerability, and expand therapeutic options for patients with BCC.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"28-34"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlapping Sarcoidosis and Atopic Dermatitis in a Black American Female: Case Report of a Rare Coexistence and Novel Treatment Approach.","authors":"Margaret G Mercante, Emily G Tocco, Diego R Dasilva","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sarcoidosis and atopic dermatitis (AD) are chronic inflammatory conditions with distinct immunologic profiles but overlapping disparities in prevalence and severity among Black Americans populations. We report a rare case of a 58-year-old Black woman with refractory cutaneous sarcoidosis and AD overlap, who presented with severely pruritic, erythematous, scaly lesions primarily on the face, scalp, and neck. Histopathologic examination revealed granulomatous inflammation. Standard topical and systemic therapies were ineffective. Initiation of upadacitinib, a selective Janus kinase (JAK) inhibitor, resulted in dramatic symptom improvement within 1 month, with a pruritus reduction from a peak pruritus Numeric Rating Scale score of 9/10 to 1/10. This case underscores the therapeutic potential of JAK inhibition in addressing convergent inflammatory pathways across traditionally distinct dermatoses, particularly in patients from populations at increased risk for treatment-refractory disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Celebrity Influence on Public Health: The Kardashians and Melanoma.","authors":"Mojan Deriss, Cybil Sierra Stingl, Nour Kibbi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"13-14"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Trichophyton indotineae</i> in New York: A Case Series Highlighting Diagnostic Pitfalls and Therapeutic Considerations.","authors":"Haowei Han, Valerie Foy, Mairead Moloney, Aleia Boccardi, Graham H Litchman, Sourab Choudhury","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To describe the clinical characteristics, treatment responses, and outcomes of patients with <i>Trichophyton indotineae</i> infection in New York state and to contribute to the collective knowledge necessary for appropriate antifungal stewardship and management strategies.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 20 patients with culture-confirmed <i>T. indotineae</i> infection seen across New York City between June 2023 and April 2025. Demographic data, clinical features, medical history, and treatment outcomes were collected. All patient data were deidentified, and informed consent was waived.</p><p><strong>Results: </strong>Patients were evenly distributed by gender, with a mean age of 43.8 years for men and 33.4 years for women. All patients reported pruritus and, notably, 90% had intact immune function. Common presentations included tinea corporis and tinea cruris. Itraconazole was the most effective first-line therapy; however, there was a high rate of recurrence after stopping the treatment. Griseofulvin, voriconazole, and fluconazole showed some success.</p><p><strong>Limitations: </strong>This study is limited by a small sample size and reliance on self-reported medical histories. Additionally, the study did not assess the impact of topical antifungal use or combination oral antifungal therapy on treatment efficacy.</p><p><strong>Conclusion: </strong><i>T. indotineae</i> presents diagnostic and therapeutic challenges due to its atypical clinical features and antifungal resistance. Early recognition and appropriate systemic antifungal therapy are critical. Itraconazole remains the preferred first-line agent based on current clinical experience. Greater clinician awareness and further research are urgently needed to address the rising burden of this infection.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"35-43"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Approach to Hyperpigmentation: Unveiling Enhanced Aesthetic Results With Microneedling and Pigment-Correcting Peel.","authors":"Suneel Chilukuri, Isabel Diaz, Bianca Gonzalez, Lia Arvanitidou","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To demonstrate the safety and enhanced cosmetic outcomes of the combination of microneedling with a pigment-correcting peel when treating hyperpigmented skin across diverse Fitzpatrick skin types.</p><p><strong>Methods: </strong>A total of 31 patients (Fitzpatrick skin types I-V) with facial hyperpigmentation were enrolled in the study. Each participant received 2 different treatments on the face: 1 side was treated with a pigment-correcting peel combined with microneedling, while the other side received microneedling alone (3 sessions, 4 weeks apart). Assessments included Mexameter measurements, dermatologist grading, and standardized clinical imaging. Self-assessment questionnaires were completed by participants at different timepoints.</p><p><strong>Results: </strong>The 31 participants completed the study; both microneedling alone and the combination treatment were well tolerated. The combined approach yielded significantly better results according to dermatologist efficacy assessment for clarity/brightness, evenness of skin tone (pigmentation and redness), overall appearance and texture (<i>P</i><0.05), and patient perception, with 94% reporting a significant or noticeable improvement on skin discoloration/hyperpigmentation on the side treated with combination therapy and 90% reporting they prefer the results of the combination therapy vs microneedling alone (<i>P</i><0.0001).</p><p><strong>Limitations: </strong>A primary limitation of this study was the restricted assessment window, which proved to be insufficient to achieve significant clinical improvement for parameters such as fine lines, wrinkles, and pore size.</p><p><strong>Conclusion: </strong>This research showed that combining a pigment-correcting peel with microneedling can be significantly more effective at improving overall skin appearance than microneedling alone. This combined therapy was safe, well tolerated, and preferred by participants across a diverse population.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"22-26"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Chemical Reconstruction of Skin Scars (CROSS) Method With Trichloroacetic Acid (TCA) for Atrophic Scars: A Comprehensive Review on Application Techniques, Adjunct Therapies, and Complications.","authors":"Scott Stratman, Helen He","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Atrophic scars have a significant psychosocial and functional impact on quality of life. Chemical reconstruction of skin scars (CROSS) using trichloroacetic acid (TCA) has emerged as an effective procedure for targeted treatment of atrophic scars, yet application methods and efficacy vary across scar types and patient populations.</p><p><strong>Objective: </strong>To evaluate the methodology, indications, efficacy, and safety profile of the TCA CROSS technique in atrophic scarring and to compare TCA CROSS outcomes to other therapeutic modalities and assesses its adjunctive use.</p><p><strong>Methods: </strong>A PubMed literature search was performed for clinical studies evaluating TCA application in scar management; inclusion criteria focused on studies using the CROSS technique published after 2002. Two reviewers independently screened 133 results: 34 publications (20 clinical trials, 4 comparative/cohort studies, 4 case series, 2 case reports, and 4 expert opinions) met eligibility criteria.</p><p><strong>Results: </strong>In total, 937 patients (predominantly female, aged 4-65 years, Fitzpatrick skin types I-V) were included. TCA CROSS was primarily used for ice pick and boxcar acne scars, but it was also used for varicella and leishmaniasis scars. Application techniques varied, with fine-gauge needles and paintbrushes enabling more precise delivery. Multiple sessions yielded greater improvement, and higher TCA concentrations increased the risk of complications. Patient satisfaction was generally high, with improvement rates of 50% to 80%. The most common adverse events were transient postinflammatory pigmentary changes.</p><p><strong>Conclusion: </strong>TCA CROSS is a safe, effective option for treating atrophic scars. Methodical application and multimodality approaches optimize patient outcomes; further research should address technique standardization and efficacy across diverse skin types.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"52-67"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Series of Hypopigmented Confluent and Reticulated Papillomatosis.","authors":"Fahad Siddiqui, Ann Church, Rajiv Nathoo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Confluent and reticulated papillomatosis (CARP) is a rare keratinization disorder typically presenting as hyperpigmented, scaly papules that coalesce into reticulated plaques on the trunk of adolescents and young adults. Hypopigmented variants have only rarely been reported and are frequently misdiagnosed as tinea versicolor, resulting in delayed diagnosis and unnecessary antifungal therapy. We describe 2 young adults with biopsy-confirmed hypopigmented CARP who initially received multiple courses of oral and topical antifungal agents with minimal to no benefit. Both patients demonstrated widespread hypopigmented, scaly, coalescing plaques. Following histopathologic confirmation, antifungal treatments were discontinued, and oral minocycline was initiated, leading to clinical improvement. These cases add to the limited literature describing hypopigmented CARP and underscore that the disease's defining features are distribution and morphology rather than pigmentation. Recognition of this rarely reported variant is essential for timely diagnosis and initiation of appropriate treatment.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"46-48"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Non-Negotiable Prerequisite: Why Primary or Acute Care Experience Is Foundational for Aesthetic Providers.","authors":"Lori J Robertson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the critical necessity of a foundational background in primary or acute care for physicians, nurses, nurse practitioners (NPs), and physician associates (PAs) transitioning into the specialty of medical aesthetics, focusing on the identification of previously missed or undiagnosed health issues and enhanced patient safety.</p><p><strong>Main points of discussion: </strong>The aesthetic medicine industry has seen a surge in providers from diverse backgrounds. However, without the diagnostic rigor and comprehensive patient assessment skills gleaned in primary or acute care settings, practitioners are at risk of overlooking significant medical conditions that can impact treatment outcomes, patient safety, and overall wellbeing. This article discusses how extensive experience in both acute care and general medicine provide the essential competencies needed to identify subtle red flags missed by others, manage complex comorbidities, and respond effectively to health emergencies within the aesthetic setting. It also discusses the need for a standardized board certification in the specialty of medical aesthetics to qualify the provider's previous experience along with assessing their current aesthetic knowledge base.</p><p><strong>Conclusion: </strong>A robust background in primary or acute care should be a recognized prerequisite for physicians, nurses, NPs, and PAs entering the specialty of medical aesthetics. This foundational experience is key to developing comprehensive assessment skills, rapid health history, and differential diagnosis formation, along with developing the much needed \"gut instinct\" or \"sixth sense,\" elevating the standard of practice, ensuring comprehensive patient care, and enhancing patient safety in a specialty often focused predominantly on objective cosmetic outcomes. To assure providers have a foundational knowledge base in both medicine and aesthetics, a national certifying body with examination is recommended.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 5-6 Suppl 1","pages":"S24-S26"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Error to Insight: A Curriculum Tool for Resident Education in Patient Safety, Quality Improvement, and Adverse Event Disclosure.","authors":"Victoria Garfinkel, Kaveh Nezafati","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether a 3-part dermatology-specific curriculum improves resident competency in process mapping, root cause analysis, and adverse event disclosure.</p><p><strong>Methods: </strong>A pre-post educational intervention study was conducted in 2025 across 3 ACGME-accredited dermatology residency programs affiliated with a Texas-based academic medical center. The curriculum consisted of 3 sequential 1-hour sessions covering patient safety fundamentals, quality improvement tool application via flipped classroom, and peer-led adverse event disclosure simulation. Primary outcomes measured self-reported confidence in systems analysis, root cause analysis, and disclosure communication using 5-point Likert scales. Secondary outcomes assessed the knowledge of dermatology-specific error types and disclosure components. Twenty-seven residents completed pre-intervention surveys and 20 completed post-intervention surveys. Data were analyzed using Mann-Whitney <i>U</i> test and Fisher exact test.</p><p><strong>Results: </strong>Residents demonstrated significant improvements across all primary competencies. Median confidence in process mapping increased from 1 to 4 (<i>P</i><0.001), fishbone diagramming from 2 to 4 (<i>P</i><0.001), and adverse event disclosure from 3 to 4 (<i>P</i>=0.001). Knowledge of common outpatient dermatology error types improved from 7.4% to 60% correct responses (<i>P</i>=0.00019). No significant differences were observed by postgraduate year level. Postcourse evaluations showed 95% rated duration as appropriate and 100% reported improved knowledge.</p><p><strong>Limitations: </strong>Study limitations include reliance on self-reported measures, anonymous survey design precluding paired analysis, modest sample size, lower postintervention response rates with potential volunteer and nonresponse bias due to voluntary participation, and single-institution implementation without long-term follow-up assessment; the curriculum was locally developed without external funding or institutional support that influenced its design or implementation.</p><p><strong>Conclusion: </strong>This dermatology-specific curriculum significantly improved resident competencies in systems analysis, root cause analysis, and adverse event disclosure. The specialty-focused design and scalable peer-led simulation model offer a practical approach for adoption across dermatology residency programs.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 5","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}